124 related articles for article (PubMed ID: 1834050)
1. Treatment of a patient with severe menstrual migraine using the depot LHRH analogue Zoladex.
Holdaway IM; Parr CE; France J
Aust N Z J Obstet Gynaecol; 1991 May; 31(2):164-5. PubMed ID: 1834050
[TBL] [Abstract][Full Text] [Related]
2. Suppression of ovarian activity by Zoladex depot (ICI 118630), a long-acting luteinizing hormone releasing hormone agonist analogue.
West CP; Baird DT
Clin Endocrinol (Oxf); 1987 Feb; 26(2):213-20. PubMed ID: 2959405
[TBL] [Abstract][Full Text] [Related]
3. The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer.
Williams MR; Walker KJ; Turkes A; Blamey RW; Nicholson RI
Br J Cancer; 1986 May; 53(5):629-36. PubMed ID: 2941044
[TBL] [Abstract][Full Text] [Related]
4. Treatment of pre-menopausal advanced breast cancer with goserelin--a long-acting luteinizing hormone releasing hormone agonist.
Brambilla C; Escobedo A; Artioli R; Lechuga MJ; Motta M
Anticancer Drugs; 1992 Feb; 3(1):3-8. PubMed ID: 1535804
[TBL] [Abstract][Full Text] [Related]
5. Endocrinologic and clinical evaluation following a single administration of a gonadotrophin-releasing hormone agonist (Zoladex), in a depot formulation, to premenopausal women.
Matta WH; Shaw RW; Burford GD
Fertil Steril; 1988 Jan; 49(1):163-5. PubMed ID: 2961621
[TBL] [Abstract][Full Text] [Related]
6. Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.
Ahmann FR; Citrin DL; deHaan HA; Guinan P; Jordan VC; Kreis W; Scott M; Trump DL
J Clin Oncol; 1987 Jun; 5(6):912-7. PubMed ID: 2953870
[TBL] [Abstract][Full Text] [Related]
7. Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group.
Kaufmann M; Jonat W; Kleeberg U; Eiermann W; Jänicke F; Hilfrich J; Kreienberg R; Albrecht M; Weitzel HK; Schmid H
J Clin Oncol; 1989 Aug; 7(8):1113-9. PubMed ID: 2526863
[TBL] [Abstract][Full Text] [Related]
8. Prolactin and pituitary gonadotropin values and responses to acute luteinizing hormone-releasing hormone (LHRH) challenge in patients having long-term treatment with a depot LHRH analogue.
Mahler C; Verhelst J; Chaban M; Denis L
Cancer; 1991 Feb; 67(3):557-9. PubMed ID: 1824680
[TBL] [Abstract][Full Text] [Related]
9. Medical castration with zoladex: a conservative approach to premenopausal breast cancer.
Brambilla C; Escobedo A; Artioli R; Lechuga MJ; Motta M; Bonadonna G
Tumori; 1991 Apr; 77(2):145-50. PubMed ID: 1828640
[TBL] [Abstract][Full Text] [Related]
10. Endocrine effects of goserelin, a new depot luteinising hormone releasing hormone agonist.
Thomas EJ; Jenkins J; Lenton EA; Cooke ID
Br Med J (Clin Res Ed); 1986 Nov; 293(6559):1407-8. PubMed ID: 2948607
[No Abstract] [Full Text] [Related]
11. Treatment of advanced prostatic carcinoma with a slow release depot LHRH analogue (Zoladex depot).
Lukkarinen O; Kontturi M
Scand J Urol Nephrol Suppl; 1988; 110():109-12. PubMed ID: 2973121
[TBL] [Abstract][Full Text] [Related]
12. Endocrine and antitumor effects of combined treatment with an antiprogestin and antiestrogen or luteinizing hormone-releasing hormone agonist in female rats bearing mammary tumors.
Bakker GH; Setyono-Han B; Portengen H; De Jong FH; Foekens JA; Klijn JG
Endocrinology; 1989 Sep; 125(3):1593-8. PubMed ID: 2527151
[TBL] [Abstract][Full Text] [Related]
13. The effect of danazol and the LHRH agonist analogue goserelin (Zoladex) on the biological activity of luteinizing hormone in women with endometriosis.
Maouris P; Dowsett M; Rose G; Edmonds DK; Rothwell C; Robertson WR
Clin Endocrinol (Oxf); 1990 Oct; 33(4):539-46. PubMed ID: 2146047
[TBL] [Abstract][Full Text] [Related]
14. Treatment of prostatic cancer by monthly injections of an LHRH-analogue depot.
Hjertberg H; Varenhorst E; Svensson M; Kågedal B; Nordenskjöld B
Acta Oncol; 1988; 27(4):361-4. PubMed ID: 2974290
[TBL] [Abstract][Full Text] [Related]
15. LH-RH agonist, Zoladex (Goserelin), depot formulation in the treatment of prostatic cancer. Randomized dose-finding trial in Japan.
Kotake T; Usami M; Sonoda T; Matsuda M; Okajima E; Osafune M; Isurugi K; Akaza H; Saitoh Y
Am J Clin Oncol; 1988; 11 Suppl 2():S108-11. PubMed ID: 2977262
[TBL] [Abstract][Full Text] [Related]
16. [Chemical castration using a depot LHRH-agonist as a palliative therapy concept in prostatic carcinoma--clinical, endocrinological and experimental studies].
Kuber W; Treu T; Kratzik C; Girsch E; Zeillinger R; Spona J
Wien Klin Wochenschr; 1990 Nov; 102(21):640-7. PubMed ID: 2148044
[TBL] [Abstract][Full Text] [Related]
17. [Preoperative reduction of uterine leiomyoma by the GnRH-analog goserelin (zoladex)].
Hackenberg R; Gesenhues T; Deichert U; Duda V; Sturm G; Schulz KD
Geburtshilfe Frauenheilkd; 1990 Feb; 50(2):136-9. PubMed ID: 2138580
[TBL] [Abstract][Full Text] [Related]
18. Potential role for medroxyprogesterone acetate as an adjunct to goserelin (Zoladex) in the medical management of uterine fibroids.
West CP; Lumsden MA; Hillier H; Sweeting V; Baird DT
Hum Reprod; 1992 Mar; 7(3):328-32. PubMed ID: 1534089
[TBL] [Abstract][Full Text] [Related]
19. Suppression of gonadotrophin secretion does not reverse premature ovarian failure.
Ledger WL; Thomas EJ; Browning D; Lenton EA; Cooke ID
Br J Obstet Gynaecol; 1989 Feb; 96(2):196-9. PubMed ID: 2522795
[TBL] [Abstract][Full Text] [Related]
20. Luteinizing hormone-releasing hormone analog therapy of uterine fibroid: analysis of results obtained with buserelin administered intranasally and goserelin administered subcutaneously as a monthly depot.
Costantini S; Anserini P; Valenzano M; Remorgida V; Venturini PL; De Cecco L
Eur J Obstet Gynecol Reprod Biol; 1990 Oct; 37(1):63-9. PubMed ID: 2142921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]